Pfizer (NYSE:PFE) Trading Up 1.3% – What’s Next?

Pfizer Inc. (NYSE:PFE) rose 1.3% during trading on Friday . The company traded as high as $26.12 and last traded at $26.0250. Approximately 46,897,005 shares were traded during trading, a decline of 9% from the average daily volume of 51,285,859 shares. The stock had previously closed at $25.70.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. Guggenheim raised their price objective on Pfizer from $33.00 to $35.00 and gave the company a “buy” rating in a research note on Monday, November 24th. Sanford C. Bernstein reissued a “market perform” rating and issued a $30.00 price target on shares of Pfizer in a research report on Friday, October 31st. Citigroup began coverage on shares of Pfizer in a research note on Tuesday. They issued a “neutral” rating and a $26.00 price objective for the company. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Finally, Bank of America lifted their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Pfizer has an average rating of “Hold” and an average price target of $28.39.

Pfizer Price Performance

The firm has a market cap of $147.97 billion, a P/E ratio of 15.13 and a beta of 0.46. The stock’s 50-day moving average is $25.12 and its 200-day moving average is $24.65. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.08. The company had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, December 1st. Shareholders of record on Friday, November 7th were given a $0.43 dividend. The ex-dividend date was Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.6%. Pfizer’s dividend payout ratio (DPR) is currently 100.00%.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. GKV Capital Management Co. Inc. bought a new position in shares of Pfizer during the 1st quarter worth about $27,000. Curio Wealth LLC raised its position in Pfizer by 36,600.0% in the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 1,098 shares in the last quarter. Bayforest Capital Ltd bought a new position in Pfizer during the first quarter worth about $28,000. Harbor Asset Planning Inc. acquired a new stake in Pfizer during the second quarter valued at approximately $29,000. Finally, Grey Fox Wealth Advisors LLC bought a new stake in shares of Pfizer in the 3rd quarter valued at approximately $29,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.